Simcere Pharmac Grp Stock Price To Earning
| S2P Stock | EUR 0.81 0.01 1.22% |
SIMCERE PHARMAC GRP fundamentals help investors to digest information that contributes to SIMCERE PHARMAC's financial success or failures. It also enables traders to predict the movement of SIMCERE Stock. The fundamental analysis module provides a way to measure SIMCERE PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SIMCERE PHARMAC stock.
SIMCERE |
SIMCERE PHARMAC GRP Company Price To Earning Analysis
SIMCERE PHARMAC's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, SIMCERE PHARMAC GRP has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-Specialty & Generic (which currently averages 0.0) industry. The price to earning for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Cryptocurrency Center Now
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
| All Next | Launch Module |
SIMCERE Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0344 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.1 % | |||
| Shares Outstanding | 2.66 B | |||
| Shares Owned By Insiders | 69.20 % | |||
| Shares Owned By Institutions | 4.70 % | |||
| Revenue | 5.58 B | |||
| Gross Profit | 3.92 B | |||
| EBITDA | 743.59 M | |||
| Book Value Per Share | 2.31 X | |||
| Earnings Per Share | 0.05 X | |||
| Number Of Employees | 6.54 K | |||
| Beta | 0.48 | |||
| Market Capitalization | 3.75 B | |||
| Annual Yield | 0.02 % | |||
| Last Dividend Paid | 0.15 |
About SIMCERE PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SIMCERE PHARMAC GRP's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SIMCERE PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SIMCERE PHARMAC GRP based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in SIMCERE Stock
SIMCERE PHARMAC financial ratios help investors to determine whether SIMCERE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SIMCERE with respect to the benefits of owning SIMCERE PHARMAC security.